07:12 AM EST, 01/13/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Monday that the phase 3 C-POST trial showed adjuvant treatment with Libtayo led to a statistically significant and clinically meaningful improvement in the primary endpoint of disease-free survival in patients with high-risk cutaneous squamous cell carcinoma after surgery.

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death compared to placebo in an interim analysis, the company said.

The company plans to continue C-POST for additional follow-up including an analysis of the key secondary endpoint of overall survival.